CYLD Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA529795-Each-of-1 | In Stock | ₹ 52,510.00 |
PIPA529795 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 52,510.00
GST (18%): ₹ 9,451.80
Total Price: ₹ 61,961.80
Antigen
CYLD
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CYLD
Gene Alias
2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; Cyld; CYLD lysine 63 deubiquitinase; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); deubiquitinating enzyme CYLD; EAC; FLJ20180; FLJ31664; FLJ78684; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Rp1; Rp1h; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; ubiquitin-specific-processing protease CYLD; Unknown (protein for MGC:137952); USPL2
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1540
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunocytochemistry, Western Blot
Concentration
1.89 mg/mL
Formulation
PBS with 20% glycerol and 0.025% ProClin 300; pH 7
Gene Accession No.
Q9NQC7
Gene Symbols
CYLD
Immunogen
Recombinant fragment corresponding to a region within amino acids 1 and 243 of Human Cylindromatosis 1
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Recommended positive controls: 293T, A431, HeLa, HepG2
- Predicted reactivity: Mouse (95%), Rat (94%), Bovine (98%)
- Store product as a concentrated solution
- Centrifuge briefly prior to opening the vial
- CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH
- CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway
- CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway
- It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination
- Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.